drugset / Trial / NCT00578617
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
Completed
60 enrolled
Mayo Clinic
Abbott Medical Devices · collabDuke Clinical Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
Timeline
- Start
- 2006-09
- Primary completion
- 2009-02
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amiodarone | Small molecule | 200 mg | — |
| Subject | Atenolol | Other / unclassified | 50 mg | — |
| Subject | Atenolol | Other / unclassified | 100 mg | — |
| Subject | Carvedilol | Other / unclassified | 6.25 mg | — |
| Subject | Digoxin | Other / unclassified | 0.125 mg | — |
| Subject | Diltiazem | Small molecule | 180 mg | — |
| Subject | Diltiazem | Small molecule | 240 mg | — |
| Subject | Dofetilide | Small molecule | 500 ug | — |
| Subject | Metoprolol | Other / unclassified | 50 mg | — |
| Subject | Metoprolol | Other / unclassified | 100 mg | — |
| Subject | Propranolol | Small molecule | 40 mg | — |
| Subject | Propranolol | Small molecule | 80 mg | — |
| Subject | Quinidine | Small molecule | 600 mg | — |
| Subject | Quinidine | Small molecule | 900 mg | — |
| Subject | Verapamil | Other / unclassified | 180 mg | — |
| Subject | Verapamil | Other / unclassified | 240 mg | — |
| Subject | acebutolol | Small molecule | 200 mg | — |
| Subject | flecainide | Small molecule | 200 mg | — |
| Subject | propafenone | Unknown | 450 mg | — |
| Subject | sotalol | Small molecule | 240 mg | — |